Candriam Luxembourg S.C.A. reduced its position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 57.1% during the second quarter, Holdings Channel reports. The firm owned 30,000 shares of the biopharmaceutical company’s stock after selling 40,000 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Theravance Biopharma were worth $1,195,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Ameritas Investment Partners Inc. increased its position in shares of Theravance Biopharma by 1,494.3% in the first quarter. Ameritas Investment Partners Inc. now owns 3,635 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 3,407 shares during the period. Aperio Group LLC purchased a new position in shares of Theravance Biopharma during the second quarter worth approximately $205,000. Harvest Management LLC purchased a new position in shares of Theravance Biopharma during the first quarter worth approximately $228,000. OMERS ADMINISTRATION Corp increased its position in shares of Theravance Biopharma by 31.9% in the first quarter. OMERS ADMINISTRATION Corp now owns 9,500 shares of the biopharmaceutical company’s stock worth $350,000 after buying an additional 2,300 shares during the period. Finally, Principal Financial Group Inc. purchased a new position in shares of Theravance Biopharma during the first quarter worth approximately $420,000. Hedge funds and other institutional investors own 84.10% of the company’s stock.

Theravance Biopharma, Inc. (NASDAQ:TBPH) opened at 24.10 on Friday. The firm’s market cap is $1.30 billion. The company’s 50 day moving average price is $35.84 and its 200 day moving average price is $35.42. Theravance Biopharma, Inc. has a 52-week low of $23.15 and a 52-week high of $43.44.

COPYRIGHT VIOLATION WARNING: This article was published by Daily Political and is the property of of Daily Political. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/08/13/candriam-luxembourg-s-c-a-sells-40000-shares-of-theravance-biopharma-inc-nasdaqtbph.html.

TBPH has been the subject of a number of analyst reports. BidaskClub cut Theravance Biopharma from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 2nd. Cantor Fitzgerald set a $55.00 price target on Theravance Biopharma and gave the stock a “buy” rating in a research report on Wednesday, July 19th. Needham & Company LLC boosted their price target on Theravance Biopharma from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, May 11th. Leerink Swann set a $47.00 price target on Theravance Biopharma and gave the stock a “buy” rating in a research report on Wednesday, May 10th. Finally, ValuEngine cut Theravance Biopharma from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Four investment analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $41.13.

In other Theravance Biopharma news, CEO Rick E. Winningham purchased 10,000 shares of Theravance Biopharma stock in a transaction that occurred on Friday, August 11th. The stock was acquired at an average price of $24.50 per share, for a total transaction of $245,000.00. Following the completion of the acquisition, the chief executive officer now owns 866,377 shares of the company’s stock, valued at approximately $21,226,236.50. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Henrietta Fore purchased 6,000 shares of Theravance Biopharma stock in a transaction that occurred on Friday, August 11th. The shares were acquired at an average price of $23.99 per share, with a total value of $143,940.00. Following the acquisition, the director now directly owns 24,000 shares of the company’s stock, valued at approximately $575,760. The disclosure for this purchase can be found here. Company insiders own 6.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Want to see what other hedge funds are holding TBPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Theravance Biopharma, Inc. (NASDAQ:TBPH).

Institutional Ownership by Quarter for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.